Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Cash (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Change in Cash for 15 consecutive years, with $498000.0 as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 95.94% to $498000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.1 million through Dec 2025, up 16.11% year-over-year, with the annual reading at $20.1 million for FY2025, 16.11% up from the prior year.
  • Change in Cash for Q4 2025 was $498000.0 at Niagen Bioscience, down from $3.8 million in the prior quarter.
  • The five-year high for Change in Cash was $28.0 million in Q1 2021, with the low at -$7.2 million in Q1 2022.
  • Average Change in Cash over 5 years is $2.4 million, with a median of $525000.0 recorded in 2023.
  • The sharpest move saw Change in Cash crashed 500.57% in 2021, then skyrocketed 4465.0% in 2025.
  • Over 5 years, Change in Cash stood at -$4.9 million in 2021, then skyrocketed by 247.02% to $7.2 million in 2022, then crashed by 92.31% to $552000.0 in 2023, then surged by 2121.38% to $12.3 million in 2024, then crashed by 95.94% to $498000.0 in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $498000.0, $3.8 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.